12 December 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the submission and review process for biosimilars through CADTH’s Common Drug Review and pan-Canadian Oncology Drug Review programs. 

Based on feedback from stakeholders, CADTH will be implementing a revised process for biosimilars. 

CADTH is currently finalising the details of the revised biosimilar review process with complete details to be announced in February 2018.

Read CADTH News article